Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.80
  • Today's Change0.20 / 3.57%
  • Shares traded325.70k
  • 1 Year change-44.76%
  • Beta2.3838
Data delayed at least 20 minutes, as of Feb 06 2026 15:46 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

  • Revenue in GBP (TTM)2.22m
  • Net income in GBP-15.08m
  • Incorporated2018
  • Employees45.00
  • Location
    Renalytix PLCFinsgate, 5-7 Cranwood StreetLONDON EC1V 9EEUnited KingdomGBR
  • Phone+44 292 071 0570
  • Websitehttps://renalytix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Proteome Sciences plc4.53m-3.33m6.16m36.00------1.36-0.0113-0.01130.0153-0.02910.50875.925.75125,750.00-37.44-8.02----17.4345.80-73.60-15.070.0774-2.512.26---2.800.9731-39.42--31.03--
Rua Life Sciences PLC5.17m-850.00k9.00m33.00--1.26--1.74-0.0137-0.01370.08320.11510.54591.186.23---9.18---10.42--77.10---16.82--3.87--0.0995--------------
Verici DX PLC1.41m-5.63m10.97m15.00--0.9582--7.76-0.0232-0.02320.00580.00760.2298--1.6778,578.60-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
Genedrive PLC954.00k-5.23m11.84m43.00--5.00--12.41-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
Cellbxhealth PLC2.62m-15.78m11.96m119.00--0.2897--4.56-0.0489-0.04890.00810.03620.10280.59391.4622,050.42-61.80-41.90-72.78-46.8162.2718.55-601.37-1,051.132.63-470.570.2387--30.92--29.34------
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Inspiration Healthcare Group PLC45.20m-11.44m15.69m214.00--0.9586--0.3472-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Renalytix PLC2.22m-15.08m24.47m45.00------11.03-0.0601-0.06010.0081-0.01560.45477.644.54---309.18-83.70---107.2540.0028.27-680.00-1,519.311.17-24.576.38--31.06--55.14------
Aptamer Group PLC1.20m-2.42m25.62m31.00--13.69--21.30-0.0014-0.00140.00070.00070.42946.274.3538,806.45-86.53---154.00--48.13---201.50--1.48-84.630.2622--39.88--18.05------
Aoti Inc47.22m1.74m44.01m80.0020.753.3512.680.9320.01990.01990.47440.12341.322.174.65--4.87--6.54--88.13--3.69--2.542.810.5269--32.88--78.55------
Ondine Biomedical Inc1.19m-12.89m46.92m43.00--102.52--39.50-0.0354-0.03540.00320.00090.34470.57718.03---373.83---4,807.85--65.77---1,084.66--0.7948--0.4333--70.32---32.51------
Inspecs Group PLC192.83m-3.31m69.64m1.65k--0.78167.460.3612-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
Creo Medical Group PLC2.20m12.60m72.18m133.005.921.195.1932.810.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
Data as of Feb 06 2026. Currency figures normalised to Renalytix PLC's reporting currency: UK Pound GBX

Institutional shareholders

47.31%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 15 Oct 202543.15m9.87%
UBS Asset Management (UK) Ltd.as of 20 Jan 202633.35m7.63%
Susquehanna Investment Group LLCas of 07 Nov 202433.00m7.55%
Ruffer LLPas of 07 Nov 202428.50m6.52%
Unicorn Asset Management Ltd.as of 15 Oct 202525.80m5.90%
abrdn, Inc.as of 30 Nov 202516.90m3.87%
Polar Capital LLPas of 15 Sep 202513.20m3.02%
Pentwater Capital Management LPas of 30 Sep 20255.79m1.32%
Harwood Capital LLPas of 31 Mar 20253.80m0.87%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 20253.27m0.75%
More ▼
Data from 30 Sep 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.